Product Details

Zofran ODT (Tablet)

Ondansetron Hydrochloride
8 mg



DIN/PIN/NPN

02239373

Manufacturer

Sandoz Canada Inc.

Formulary Listing Date

2000-04-17  

Unit Price

23.8890

Amount MOH Pays

3.8840

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AA01

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02239373 Zofran ODT (Tablet) 23.8890 3.8840
02444682 VPI-Ondansetron ODT (Tablet) 4.9930 3.8840
02389991 Ondissolve ODF (Film) 4.9930 3.8840
02481731 Ondansetron ODT (Tablet) 4.9930 3.8840
02487349 Mint-Ondansetron ODT (Tablet) 4.9930 3.8840
02511290 Auro-Ondansetron ODT (Tablet) 4.9930 3.8840
02514974 Mar-Ondansetron ODT Tablet 4.9930 3.8840
02519240 Ondansetron ODT (Tablet) 4.9930 3.8840
02519453 PMS-Ondansetron ODT Tablet 4.9930 3.8840
02524287 Ondansetron ODT (Tablet) 4.9930 3.8840
02535327 Accel-Ondansetron ODT (Tablet) 3.8840 3.8840
02541378 Jamp Ondansetron ODF 4.9930 3.8840
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
Note: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven
215 1 year

For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy

216 1 year

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics

217 1 year

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics

218 1 year

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.

454 1 year

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens

 

EAP Criteria

Therapeutic Class Reimbursement Criteria
Unclassified EAP Drugs

These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition

Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding.

Product Monograph

View Monograph